Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line continuous capecitabine plus oxaliplatin and biweekly bevacizumab in metastatic or advanced colorectal adenocarcinoma
2005-006171-12Phase 2Active
- Sponsor
- Unidad Integral de Investigación en Oncología
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bevacizumab, oxaliplatin and capecitabine in colorectal adenocarcinoma (mCRC) and colorectal adenocarcinoma, sponsored by Unidad Integral de Investigación en Oncología. Primary endpoint: Progression-free survival at 9 months. Started Apr 2006; status: active.
02
Drugs
bevacizumaboxaliplatincapecitabine
03
Conditions
colorectal adenocarcinoma (mCRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2005-006171-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006171-12.